最大的创新是销售模式。 | 作者 | | 观韬 | | --- | --- | --- | | 编辑 | | 小白 | 6月中旬，福瑞股份（300049.SZ）在其官网公布了首都医科大学中医药学院宋鑫华/王如伯团队在国 际知名期刊《Phytomedicine》发表的一项研究，首次系统揭示了其核心产品复方鳖甲软肝片抗肝内胆 管癌的双重作用机制。 该研究表明，复方鳖甲软肝片不仅能直接抑制肿瘤细胞增殖、诱导其凋亡，还能通过靶向肿瘤相关成 纤维细胞，重塑肿瘤微环境，间接发挥抗肿瘤作用。 肝内胆管癌是仅次于肝细胞肝癌的第二大肝癌，目前缺乏有效的治疗手段，患者生存期短、复发率 高。复方鳖甲软肝片还是第一个被批准治疗肝纤维化的中成药。 根据国家"十二五"、"十三五"重大专项课题历时9年的研究，联合复方鳖甲软肝片"双抗治疗"较抗病 毒单药治疗，不仅能够显著逆转慢性乙型肝炎肝纤维化肝硬化，还能明显降低肝癌和乙肝相关死亡 率。 怎么样，老铁，动心了没？ 主卖软肝片一款药 福瑞股份1998年在内蒙古乌兰察布成立，2010年1月在深交所上市，自成立起就从事肝病的诊断、服 务和药品治疗。 （公司招股书） （来源：2024年年报） 福瑞 ...

今日重点推荐 2025 年 06 月 09 日 | 指数 | 收盘 | | 涨跌（％） | | | --- | --- | --- | --- | --- | | 名称 | （点） | 1 日 | 5 日 | 1 月 | | 上证指数 | 3385 | 0.04 | 2.09 | 1.13 | | 深证综指 | 2008 | -0.12 | 2.5 | 1.82 | | 风格指数 | 昨日表现 | 1 个月表现 | 6 个月表现 | | --- | --- | --- | --- | | | （％） | （％） | （％） | | 大盘指数 | -0.14 | 1.68 | -2.18 | | 中盘指数 | 0 | 0.46 | -6.34 | | 小盘指数 | -0.19 | 0.58 | -2.23 | | 行业涨幅 | 昨日涨 | 1 个月涨 | 6 个月涨 | | 油服工程 | 1.78 | 3.91 | -5.97 | | 非金属材料 | 1.7 | -1.18 | 2.55 | | Ⅱ 工业金属 | 1.68 | 2.73 | 4.18 | | 农化制品 | 1.58 | 6.87 | -0.77 ...

Core Viewpoint - The company held its 2024 annual performance briefing, where it engaged with investors and addressed various inquiries regarding its business strategies and performance metrics. Group 1: Company Performance - In 2024, the company achieved total revenue of 1.349 billion yuan, representing a year-on-year growth of 16.93% [6] - The net profit attributable to shareholders was 113 million yuan, an increase of 11.54% year-on-year [6] - The company's proprietary drug business generated 283 million yuan in revenue, marking a 44.31% increase compared to the previous year [6][7] Group 2: Business Strategy - The company is focused on a management-style medical strategy, which has led to a revenue growth of 25%-30% in its pharmaceutical and medical services sectors [4] - The company aims to enhance its digital health management services, covering the entire patient lifecycle, to improve drug sales and patient compliance [4][7] - The company plans to optimize its liver disease patient management system in response to the "Healthy China 2030" initiative [4] Group 3: Market Position and Future Outlook - The domestic market accounted for 36.72% of revenue, while the international market contributed 63.28% in 2024 [4] - The company is committed to becoming a professional and international management-style medical group, focusing on liver cancer screening and management [4][7] - The company anticipates that the market for its products will enter a rapid growth phase following the approval of the MASH indication by the FDA [4][8] Group 4: Product and Service Development - The company has developed a full-cycle management solution for liver disease, integrating screening, diagnosis, and treatment [4][7] - The FibroScan Go and box products have been installed in 651 units globally, becoming new revenue growth points for the company [7] - The company is enhancing its marketing strategies for its proprietary drugs and expanding its e-commerce channels to sustain high growth rates [6][7]